New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 2, 2013, Pages 327-335

  Kozanoglu, Ilknur ^a   Yandim, Melis Kartal ^b   Cincin, Zeynep Birsu ^c   Ozdogu, Hakan ^a   Cakmakoglu, Bedia ^c   Baran, Yusuf ^b  

^a BASKENT UNIVERSITY   (Turkey)

^b IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Multiple myeloma; NF B pathway; Propranolol

Indexed keywords

CASPASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLSERINE; PROPRANOLOL; PROTEIN BCL 10; PROTEIN BCL 2; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 10B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; GENETICS; METABOLISM; MITOCHONDRION; SIGNAL TRANSDUCTION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ADRENERGIC BETA-ANTAGONISTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MULTIPLE MYELOMA; NF-KAPPA B; PROPRANOLOL; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 84874992804     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1331-y     Document Type: Article

References (40)

1. Algazi M, Plu-Bureau G, Flahault A, Dondon MG, Lê MG (2004) Could treatments with beta-blockers be associated with a reduction in cancer risk? Rev Epidemiol Sante Publique 52:53-65
2. Annabi B, Lachambre MP, Plouffe K, Moumdjian R, Béliveau R (2009) Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 60:438-445
3. Benish M, Bartal I, Goldfarb Y, Levi B, Avraham R, Raz A, Ben-Eliyahu S (2008) Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 15:2042-2052
4. Benjamin B, Hazut O, Shaashua L, Benish M, Zmora N, Barshack I, Hoffman A, Ben-Eliyahu S, Zmora O (2010) Effect of beta blocker combined with COX-2 inhibitor on colonic anastomosis in rats. Int J Colorectal Dis 25:1459-1464
5. Bradley JR, Pober JS (2001) Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 20:6482-6491
6. Buckmiller LM, Munson PD, Dyamenahalli U, Dai Y, Richter GT (2010) Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. Laryngoscope 120:676-681
7. Connolly DJ, O'Neill LA (2012) New developments in toll-like receptor targeted therapeutics. Curr Opin Pharmacol. doi: 10.1016/j.coph.2012.06.002
8. Davoodi H, Hashemi SR, Seow HF (2012) Increased NFk-B activity in HCT116 colorectal cancer cell line harboring TLR4 Asp299Gly variant. Iran J Allergy Asthma Immunol 11:121-132
9. Do KN, Fink LN, Jensen TE, Gautier L, Parlesak A (2012) TLR2 controls intestinal carcinogen detoxication by CYP1A1. PLoS ONE 7:e32309
10. Du MQ, Isaccson PG (2002) Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 3:97-104
11. Elouni B, Ben Salem C, Zamy M, Sakhri J, Bouraoui K, Biour M (2010) Bortezomib-induced acute pancreatitis. JOP 11:275-276
12. Emilien G, Maloteaux JM (1998) Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol 53:389-404
13. Eskdale J, Kube D, Tesch H, Gallagher G (1997) Mapping of the human IL10 gene and further characterization of the 5′ flanking sequence. Immunogenetics 46:120-128
14. Featherstone HJ (1983) Low-dose propranolol therapy for aborting migraine. West J Med 138:416-417
15. Frohlich ED (1977) Pathophysiology of propranolol in hypertension. South Med J 70:95-99
16. Glasner A, Avraham R, Rosenne E, Benish M, Zmora O, Shemer S, Meiboom H, Ben-Eliyahu S (2010) Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 184:2449-2457
17. Kang MR, Kang JS, Yang JW, Kim BG, Kim JA, Jo YN, Lee K, Lee CW, Lee KH, Yun J, Kim HM, Han G, Kang JS, Park SK (2012) Gene expression profiling of KBH-A42, a novel histone deacetylase inhibitor, in human leukemia and bladder cancer cell lines. Oncol Lett 3:113-118
18. Karnak D, Xu L (2010) Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets 11:699-707
19. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A (2008) Propranolol for severe hemangiomas of infancy. N Engl J Med 358:2649-2651
20. Lee TC, Coffey RJ, Currier BM, Ma XP, Canary JJ (1982) Propranolol and thyroidectomy in the treatment of thyrotoxicosis. Ann Surg 195:766-773
21. Levine B, Sinha S, Kroemer G (2008) Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 4:600-606
22. Love JN, Sikka N (2004) Are 1-2 tablets dangerous? Beta-blocker exposure in toddlers. J Emerg Med 26:309-314
23. Mahindra A, Hideshima T, Anderson KC (2010) Multiple myeloma: biology of the disease. Blood Rev 24:5-11
24. Marquez RT, Xu L (2012) Bcl-2:Beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch. Am J Cancer Res 2:214-221
25. Masur K, Niggemann B, Zanker KS, Entschladen F (2001) Norepinephrine-induced migration of SW480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 61:2866-2869
26. Metry D, Frieden IJ, Hess C, Siegel D, Maheshwari M, Baselga E, Chamlin S, Garzon M, Mancini AJ, Powell J, Drolet BA (2012) Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants. Pediatr Dermatol. doi: 10.1111/j.1525-1470.2012.01879. x. http://www.ncbi.nlm.nih.gov/pubmed/22994362
27. Minnema MC, van der Spek E, van de Donk NW, Lokhorst HM (2010) New developments in the treatment of patients with multiple myeloma. Neth J Med 68:24-32
28. Park PG, Merryman J, Orloff M, Schuller HM (1995) Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res 55:3504-3508
29. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K (2007) New drugs for myeloma. Oncologist 12:664-689
30. Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J et al (2009) Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 124:423-431
31. Sarialioglu F, Erbay A, Demir S (2010) Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-α therapy. Pediatr Blood Cancer 55:1433-1434
32. Sidbury R (2010) Update on vascular tumors of infancy. Curr Opin Pediatr 22:432-437
33. Slotkin TA, Zhang J, Dancel R, Garcia SJ, Willis C, Seidler FJ (2000) Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 60:153-166
34. Sommers Smith SK, Smith DM (2002) Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim 38:298-304
35. Storch CH, Hoeger PH (2010) Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 163:269-274
36. Takimoto R, El-Deiry WS (2000) Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19:1735-1743
37. Wajant H, Henkler F, Scheurich P (2001) The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators. Cell Signal 13:389-400
38. Willis TG, Jadayel DM, Du MQ, Peng H, Perry AR, Abdul-Rauf M, Price H, Karran L, Majekodunmi O, Wlodarska I, Pan L, Crook T, Hamoudi R, Isaacson PG, Dyer MJ (1999) Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96:35-45
39. Yoneda T, Imaizumi K, Maeda M, Yui D, Manabe T, Katayama T, Sato N, Gomi F, Morihara T, Mori Y, Miyoshi K, Hitomi J, Ugawa S, Yamada S, Okabe M, Tohyama M (2000) Regulatory mechanisms of TRAF2-mediated signal transduction by Bcl10, a MALT lymphoma-associated protein. J Biol Chem 275:11114-11120
40. Zusman R, Christensen D, Federman E, Kochar MS, McCarron D, Porush JG, Spitalewitz S (1987) Comparison of nifedipine and propranolol used in combination with diuretics for the treatment of hypertension. Am J Med 82(3B):37-41. http://www.ncbi.nlm.nih.gov/pubmed/3551602